Fundz

Acrivon Therapeutics, Inc. reported raising $15.5 Million in an initial SEC Form D filing, from an offering of $15.5 Million

PUBLIC · ACRVFeb 12, 2021

Amount Raised

$15.5 Million

$15.5 Million sold, per SEC Form D (first sale Feb 12, 2021)

Round Type

Venture

WatertownBiotechnologyHealth CareMedicalTherapeuticsBiopharma

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Acrivon Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Qihan Biotech raised $67M (Series A) on March 29, 2021.
  • Scipher Medicine raised $82M on March 26, 2021.
  • Camp4 Therapeutics Corp raised $15M on March 19, 2021.
  • Century Therapeutics, Inc. raised an undisclosed amount on March 15, 2021.
  • Oragenics raised $21M (Series C) on February 12, 2021.
  • Day One Biopharmaceuticals raised $130M (Series B) on February 10, 2021.

Who to call at Acrivon Therapeutics, and when

A new round usually means Acrivon Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Acrivon Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Acrivon Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Acrivon Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Acrivon Therapeutics

Location

480 Arsenal Way Suite 100

Watertown, Massachusetts, United States

About

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Acrivon Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsMary-Alice, Chief Legal Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Acrivon Therapeutics's next move

See what Strategic adds

Acrivon Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.